HC Wainwright Forecasts Strong Price Appreciation for Denali Therapeutics (NASDAQ:DNLI) Stock

Denali Therapeutics (NASDAQ:DNLI) had its target price hoisted by equities research analysts at HC Wainwright from $32.00 to $42.00 in a research report issued to clients and investors on Thursday, Marketbeat Ratings reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price would indicate a potential upside of 131.28% from the stock’s current price.

DNLI has been the subject of a number of other research reports. BTIG Research boosted their price target on Denali Therapeutics from $32.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Jefferies Financial Group restated a “buy” rating and issued a $40.00 price objective on shares of Denali Therapeutics in a report on Monday, March 2nd. Wedbush reduced their price objective on Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating on the stock in a research note on Thursday, December 11th. UBS Group started coverage on Denali Therapeutics in a report on Wednesday, January 7th. They set a “buy” rating for the company. Finally, Wolfe Research started coverage on shares of Denali Therapeutics in a research report on Monday, February 23rd. They set a “peer perform” rating for the company. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $34.82.

Denali Therapeutics Stock Performance

NASDAQ:DNLI opened at $18.16 on Thursday. The company has a market cap of $2.88 billion, a P/E ratio of -6.11 and a beta of 1.02. The firm’s 50 day moving average is $20.43 and its two-hundred day moving average is $17.83. Denali Therapeutics has a fifty-two week low of $10.57 and a fifty-two week high of $23.77. The company has a quick ratio of 9.16, a current ratio of 9.16 and a debt-to-equity ratio of 0.01.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.02. During the same quarter in the previous year, the firm earned ($0.67) EPS. Analysts expect that Denali Therapeutics will post -2.71 EPS for the current year.

Insider Buying and Selling at Denali Therapeutics

In other Denali Therapeutics news, CEO Ryan J. Watts sold 35,198 shares of the business’s stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total transaction of $580,767.00. Following the transaction, the chief executive officer owned 296,833 shares in the company, valued at $4,897,744.50. The trade was a 10.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Alexander O. Schuth sold 17,218 shares of the company’s stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total value of $284,097.00. Following the completion of the sale, the insider directly owned 282,828 shares of the company’s stock, valued at $4,666,662. The trade was a 5.74% decrease in their position. The disclosure for this sale is available in the SEC filing. 12.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Denali Therapeutics

Several hedge funds have recently modified their holdings of DNLI. Norges Bank acquired a new position in Denali Therapeutics during the 4th quarter worth approximately $84,525,000. Holocene Advisors LP grew its position in Denali Therapeutics by 677.8% in the third quarter. Holocene Advisors LP now owns 3,135,712 shares of the company’s stock valued at $45,531,000 after acquiring an additional 2,732,540 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Denali Therapeutics by 77.3% during the fourth quarter. Goldman Sachs Group Inc. now owns 3,835,803 shares of the company’s stock valued at $63,329,000 after purchasing an additional 1,672,098 shares during the period. Temasek Holdings Private Ltd raised its stake in shares of Denali Therapeutics by 30.9% during the fourth quarter. Temasek Holdings Private Ltd now owns 7,012,974 shares of the company’s stock valued at $115,784,000 after purchasing an additional 1,657,142 shares during the period. Finally, T. Rowe Price Investment Management Inc. lifted its position in shares of Denali Therapeutics by 28.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 7,254,132 shares of the company’s stock worth $119,766,000 after purchasing an additional 1,615,565 shares in the last quarter. 92.92% of the stock is currently owned by hedge funds and other institutional investors.

More Denali Therapeutics News

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: FDA approval of AVLAYAH — AVLAYAH received FDA approval as a brain‑targeting therapy for Hunter syndrome, giving Denali its first approved commercial asset and creating a clear commercialization pathway. Denali Wins FDA Nod for Hunter Syndrome Drug, Stock Up
• Positive Sentiment: Morgan Stanley raised its price target to $42 and kept an overweight rating — a large revision implying ~131% upside vs. the current price, signaling strong sell‑side confidence post‑approval. Benzinga
• Positive Sentiment: Goldman Sachs raised its target to $40 and reiterated a buy — another high target reflecting elevated expectations for AVLAYAH’s commercial prospects. Benzinga
• Positive Sentiment: Stifel, BTIG, HC Wainwright, Robert W. Baird also raised targets and/or ratings — most moved targets into the $32–$42 range and maintained buy/outperform views, adding upward pressure on the stock. (Sources include Benzinga and TickerReport.) Benzinga TickerReport
• Neutral Sentiment: Company discussion/transcript on commercial launch plans — management provided details on launch timing, supply and go‑to‑market strategy in a call/transcript, helping investors assess execution risk but not immediately changing fundamentals. Denali Discusses FDA Approval and Commercial Launch Plans for AVLAYAH (Transcript)
• Neutral Sentiment: Wider media coverage — outlets (MSN, Business Insider, Seeking Alpha) reported the FDA approval and will likely broaden investor and clinician awareness; coverage supports sentiment but execution and uptake remain the next items to watch. MSN Business Insider

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.